Dublin, Ireland-headquartered protein specialist Prothena (Nasdaq: PRTA) has published results from the Phase III VITAL trial in a journal of the American Society of Hematology (ASH).
A post hoc analysis of certain people with AL amyloidosis shows a statistically-significant survival benefit of 74% for those treated with birtamimab, an antibody designed to clear the dysregulated proteins that are a hallmark of the condition.
People in the trial were given standard of care and either birtamimab or a placebo, with the latter cohort achieving a 49% survival benefit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze